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Abstract
Previously it was shown that neuropeptide cyclo-L-prolylglycine (CPG) is a
positive modulator of AMPA receptors, which increases BDNF level in neuronal cell
cultures. The spectrum of CPG’s pharmacological effects corresponds to that of
BDNF. Dipeptide N-phenylacetyl-glycyl-L-proline ethyl ester (GZK-111) was
designed and synthesized as a linear analog of CPG. The aim of the present work
was to reveal the pharmacological profile of GZK-111. Dipeptide GZK-111 was
shown to metabolize into CPG in vitro and increased cell survival by 28% at
concentrations of 10-7–10-6 M in a Parkinson’s disease cell model. In a model of
cerebral ischemia, GZK-111, at a dose of 0.5 mg/kg, i.p., was found to have
neuroprotective effects, reducing the cerebral infarct volume by 1.6 times. Similar
to CPG, GZK-111, at the range 0.1–1.0 mg/kg, i.p., possessed a stereospecific
antiamnesic activity. A significant anxiolytic effect was observed at a dose of 1.5
mg/kg. GZK-111, at the range 0.5–4.0 mg/kg, i.p., demonstrated analgesic activity.
GZK-111, at a dose of 10 mg/kg/7 days, i.p., possessed antidepressant-like activity.
So, the neuroprotective, nootropic, antihypoxic, anxiolytic, antidepressant-like, and
analgesic effects of GZK-111 were revealed. Thus, GZK-111 can be considered as a
pharmacologically active pro-ampakine with a BDNF-ergic mechanism of action.
Keywords: glyproline GZK-111, pro-ampakine, cyclo-prolylglycine, BDNF,
neuroprotective activity
1. Introduction
Cyclo-L-prolylglycine (CPG) was designed as a potential peptide prototype of
piracetam, the classic nootropic drug [1] and was subsequently discovered as
endogenous compound in the brain of intact rats in micromolar concentration [2].
CPG is similar to piracetam both in structure and main pharmacological effects; it
possesses nootropic [3], anxiolytic [4, 5], antihypoxic [6], neuroprotective [6, 7],
analgesic [8], and antidepressant [9, 10] activities at central administration at doses
100–1000 times smaller than those for piracetam. Recently, we have demonstrated
CPG to be ampakine, i.e., a positive modulator of AMPA receptors [11]. Like other
ampakines, it increases brain-derived neurotrophic factor (BDNF) content in
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neuronal cell cultures [12]. The range of CPG pharmacological effects corresponds
both to that of piracetam and BDNF. In view of this, CPG can be regarded as a basis
for creation of new group of drugs with neuroprotective properties.
CPG is a hydrophilic compound. The task to create an amphiphilic CPG prodrug
with improved pharmacokinetic properties, converted to active molecule in the
brain, was established to increase drug passage through biological membranes,
including the blood-brain barrier. Two variants of substituted dipeptides, based on
the Pro-Gly or Gly-Pro sequence, could be used for this purpose. We selected the
second one (i.e., Gly-Pro), following the known information that an imide bond
with proline in Gly-Pro dipeptide sequence increased the proportion of the cisoid
peptide bond [13, 14], which, in turn, promoted cyclization of the dipeptide
[15, 16].
In this work, we synthesized substituted glyproline N-phenylacetyl-glycyl-L-
proline ethyl ester (GZK-111) to prove the hypothesis, confirmed the CPG forma-
tion during GZK-111 metabolism in the presence of blood plasma enzymes, and
demonstrated the compound pharmacological effects typical for CPG and BDNF,
namely, neuroprotective, nootropic, antihypoxic, anxiolytic, antidepressant, and
analgesic activities.
2. Materials and methods
2.1 Chemical experimental part
The chemical reagents used in the synthesis were obtained from commercial
suppliers and used without purification. All solvents were dried and purified by
standard procedures if required. Melting points were measured in open capillary
tubes using OptiMelt melting point apparatus (Stanford Research Systems, USA).
The structures of the compounds were confirmed by elemental analysis and 1H
NMR spectroscopy. The NMR spectra were obtained on a Bruker Fourier 300
(Bruker, Germany) spectrometer using tetramethylsilane as an internal standard.
The NMR peaks were designated as follows: s, singlet; d, doublet; t, triplet; and m,
multiplet. Microanalyses for C, H, and N agreed with calculated values within 0.4%.
Specific optical rotations were recorded by automatic polarimeter ADP 440
(Bellingham + Stanley Ltd., England). The TLC was carried out on Merck silica gel
60 F 254 plates with spot visualization by iodine vapor or UV light.
N-Phenylacetyl-glycine. 13.24 ml (0.1 mol) of N-phenylacetyl chloride and
25 ml of 4 M NaOH were added dropwise successively to a solution of 7.5 g
(0.1 mol) of glycine in 25 ml of 4 M NaOH under stirring at 10°С. The reaction
mixture was stirred for 30 min on cooling, extracted by ethyl acetate (3  15 ml) to
remove impurities and unreacted N-phenylacetyl chloride. Then the solution was
acidified by 4М HCl to pH 2–3; the resulting precipitate was filtered, washed with
cooled distilled water, and dried in air. The yield of N-phenylacetyl-glycine was
5.83 g (30%); m.p. 143–144°С; Rf 0.8 (BuOH/AcOH/H2O, 4:1:1).
1H-NMR spectrum
(DMSO-d6 + CF3COOD, d, ppm): 3.47 (s, 2Н, СН2Ar), 3.76 (d, J 6.0 Hz, 2Н, СН2
Gly), 7.27 (m, 5H, ArH), 8.40 (t, J 6.0 Hz, 1Н, NH Gly). Lit. data [17]:
m.p. 138–143°С.
H-L-Pro-OC2H5HCl. 2.54 ml (35 mmol) of thionyl chloride was added
dropwise to 60 ml of anhydrous ethanol cooled to 20°С. Then 2.0 g (17.5 mmol)
of L-proline was added portionwise under vigorous stirring. The resulting mixture
was stirred for 2 h at 5°С and then for 2 h at room temperature. The solvent was
removed in vacuo. This operation was repeated twice, each time adding 30 ml of
anhydrous ethyl alcohol to afford 2.4 g (77%) of L-proline ethyl ester hydrochloride
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as an oil. [α]23D 43° (с 3, EtOH); Rf 0.75 (i-PrOH/NH3, 7:3).
1H-NMR spectrum
(DMSO-d6, d, ppm): 1.19 (m, 3Н, СН3СН2О), 1.8–2.1 (m, 4Н, С
γ
Н2 Pro, С
β
Н2 Pro),
3.2 (m, 2Н, СδН2 Pro), 4.2 (m, 2Н, СН3СН2О), 4.5 (m, 1Н, С
α
Н Pro), 9.9 (br. s, 1Н,
NH). Lit. data [18]: oil; [α]23D 44.8° (с 3.03, EtOH).
H-D-Pro-OC2H5HCl. Obtained similarly to H-L-Pro-OC2H5HCl from
D-proline. [α]23D + 42.0° (с 3, EtOH); Rf 0.75 (i-PrOH/NH3, 7:3).
1H-NMR spectrum
(DMSO-d6, d, ppm): 1.18 (m, 3Н, СН3СН2О), 1.8–2.1 (m, 4Н, С
γ
Н2 Pro, С
β
Н2 Pro),
3.19 (m, 2Н, СδН2 Pro), 4.2 (m, 2Н, СН3СН2О), 4.5 (m, 1Н, С
α
Н Pro), 9.9 (br. s, 1Н,
NH). Lit. data [18]: oil; [α]23D +44.16° (с 3.03, EtOH).
N-Phenylacetyl-glycyl-L-proline ethyl ester. 1.1 ml (10.0 mmol) of N-
methylmorpholine and 1.35 ml (10.0 mmol) of isobutyl chloroformate were added
simultaneously at 10°C to a vigorously stirred solution of 1.93 (10.0 mmol)
N-phenylacetyl-glycine in dimethylformamide (10 mL). After 2 min a mixture of
1.79 g (10.0 mmol) of proline ethyl ester hydrochloride and 1.1 ml (10.0 mmol) of
N-methylmorpholine in dimethylformamide (20 mL) was added dropwise. The
reaction mixture was stirred at 10°C for 30 min and then at room temperature for
1 h. The precipitate was separated by filtration; the solvent was evaporated in
vacuo; the residue was dissolved in chloroform (25 ml). The solution was washed
with 3% solution of NaHCO3 (3  7 ml), water (3  7 ml), and 1 N HCl (3  7 ml).
The organic layer was dried with anhydrous Na2SO4, filtered, and evaporated to
dryness. The yield of chromatographically homogeneous product was 2.87 g (90%),
an orange oil, finally crystallized from ethyl acetate/hexane system. M.p. 111–112°C;
[a]23D 90.0° (с 1, water); Rf = 0.80 (dioxane/H2O, 9:1).
1H-NMR spectrum
(DMSO-d6, d, ppm): 1.2 (m, 3Н, СН3СН2О), 1.8–2.1 (m, 4Н, С
γ
Н2 Pro, С
β
Н2 Pro),
3.5 (s, 2Н, СН2ArH), 3.6 (m, 2Н, С
δ
Н2 Pro), 3.85 and 4.0 (2 dd, J 17.6 Hz, J 5.6 Hz,
2Н, СαН2 Gly), 4.2 (m, 2Н, СН3СН2О), 4.5 (dd, J 4.0 Hz, J 8.5 Hz, 1Н, С
α
Н Pro), 6.4
(br. t, J 5.6 Hz, 1Н, NH), 7.3 (m, 5Н, ArH). Calcd. for C17H22N2O4, %: C, 64.27; H,
7.05; N, 8.63. Found, %: C, 64.13; H, 6.97; N, 8.80.
C6H5-CH2-C(O)-Gly-D-Pro-OEt (GZK-121). Obtained similarly to the
L-enantiomer. Yield 64%. M.p. 112–113°C; [a]23D +90.0° (с 1, water); Rf = 0.80
(dioxane/H2O, 9:1).
1H-NMR spectrum (DMSO-d6, d, ppm): 1.2 (m, 3Н,
СН3СН2О), 1.85–2.2 (m, 4Н, С
γ
Н2 Pro, С
β
Н2 Pro), 3.5 (s, 2Н, СН2Ar), 3.6 (m, 2Н,
С
δ
Н2 Pro), 3.86 and 4.0 (2 dd, J 17.6 Hz, J 5.6 Hz, 2Н, С
α
Н2 Gly), 4.2 (m, 2Н,
СН3СН2О), 4.5 (dd, J 4.0 Hz, J 8.5 Hz, 1Н, С
α
Н Pro), 6.4 (br. t, J 5.6 Hz, 1Н, NH),
7.3 (m, 5Н, Ar). Calcd. for C17H22N2O4., %: C, 64.27; H, 7.05; N, 8.63. Found, %: C,
63.91; H, 6.90; N, 8.71.
2.2 Biological experimental
2.2.1 Study of GZK-111 metabolism
Blood plasma preparation. Blood plasma of outbred male rats weighing 250–280 g
was used. Animals were decapitated, blood was collected in BD Vacutainer® tubes
with EDTA, and plasma was obtained by centrifugation at 3000 rpm for 10 min.
Incubation and extraction. A solution of 3 mg of GZK-111 in 100 μl of saline was
added to 900 μl of rat plasma. The mixture was incubated at 37°C in a water bath for
10 h. Then, an equal volume of acetonitrile was added to 100 μl of the incubated
mixture, the samples were vigorously shaken for 10 min and centrifuged at
12,000 rpm for 10 min, and the supernatant was collected and then
chromatographed.
Reverse-phase high-performance liquid chromatography (RP HPLC). HPLC was
performed on a Gilson 41 chromatograph (Gilson, USA) with a Gilson 116 UV
detector (Gilson, USA). Detection was carried out at 220 nm. A Nucleosil C18
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column (4.6  150 mm, 5 μm) was used with a flow rate of 0.5 ml/min. The sample
volume was 20 μl. The following eluents were used: (solution A) 3.7 mM sodium
1-hexanesulfonate/water (pH 3.5) and (solution B) 3.7 mM sodium 1-
hexanesulfonate/40% acetonitrile. The elution was carried out in a gradient
according to the following program: (1) 0% B for 3 min, (2) from 0 to 100% B in
20 min, and (3) 100% B for 6 min. The signal was recorded using the Multichrom
1.5 software (Ampersend, RF). Cyclo-L-prolylglycine and N-phenylacetyl-glycyl-L-
proline, synthesized in the Medicinal Chemistry Department of the V.V. Zakusov
Research Institute of Pharmacology, were used as standards for HPLC.
Calibration curve. Standard solutions of synthetic cyclo-L-prolylglycine were
prepared in acetonitrile at the concentrations of 0, 0.1, 0.2, 0.4, 0.8, 1.6, and
3.2 mg/L. The 20 μl aliquot of the solutions were chromatographed under RP HPLC
conditions as described above. The calibration curve was calculated based on the
peak areas.
2.2.2 In vitro pharmacological study
Cell culture. The studies were carried out on SH-SY5Y human neuroblastoma
cells received from the cell bank of the N.N. Blokhin National Medical Research
Center of Oncology of the Ministry of Health of the Russian Federation. Cells were
grown at 37°C and 5% CO2 in DMEM (HyClone, USA) with 10% FBS (Gibco, USA)
and 2 mM L-glutamine (MP Biomedicals, Germany). After the monolayer
formation, the cells were counted and placed into 96-well culture plates
(Costar-Corning, USA) at a density of 3.5 thousand per well and into 6-well
culture plates (Costar-Corning, USA) at a density of 280 thousand per well; both
plates were pre-coated with a 0.1 mg/ml solution of poly-D-lysine (BD Bioscience,
UK) for 1 h.
Parkinson’s disease model in culture of SH-SY5Y human neuroblastoma cells. Neu-
rotoxin 6-hydroxidopamine (6-OHDA) used in an experimental model of in vitro
dopaminergic neuron degeneration according to [19] was applied to simulate
Parkinson’s disease in the culture of SH-SY5Y human neuroblastoma cells. 6-OHDA
was added into the cell medium at a final concentration of 100 μM 24 h after cell
seeding. Then the cells were incubated for 24 h. The neuroprotective effect was
investigated by addition of compounds to the culture medium at final concentra-
tions of 108–105 M 24 h before 6-OHDA. Cell viability was determined after 24 h
using the MTT test.
Neuronal viability assessment in culture using the MTT test.MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) is a yellow water-soluble
tetrazolium salt that easily penetrates into cells. In living cells, MTT transforms into
water-insoluble violet formazan crystals, which are dissolved in organic solvents
(isopropanol, dimethylformamide, dimethyl sulfoxide) upon completion of the
reaction followed by absorption measurements.
At the end of the experiment, the culture medium was replaced with MTT
solution (0.5 mg/ml) and incubated for 30 min at 37°C. Then, a MTT solution
was removed from the wells, and DMSO was added to dissolve the formazan.
Absorbance was measured at 600 nm using a 96-well plate reader Multiscan
(Thermo, USA).
2.2.3 In vivo pharmacological studies
In vivo studies were performed in outbred male rats weighing 200–270 g
(nootropic and a anxiolytic activity), in outbred male mice weighing 25–28 g
(antihypoxic and antidepressant-like activity), and in C57Bl/6 male mice weighing
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25–29 g (analgesic activity), received from the Stolbovaya Branch of the Scientific
Center of Biomedical Technologies of the Federal Medical Biological Agency
(FMBA) of Russia, and in Wistar male rats weighing 200–250 g (neuroprotective
activity) received from the Andreevka Branch of the Scientific Center of Biomedical
Technologies of the FMBA of Russia. The animals were kept in vivarium under
natural circadian light/dark cycles with free access to standard granular feed and
water. The study complied with the requirements of Order of the Ministry of Health
of the Russian Federation No. 199 “On Approval of the Rules of Good Laboratory
Practice” and Decision of the Council of the Eurasian Economic Commission No. 81
“On Approval of the Rules of Good Laboratory Practice of the Eurasian Economic
Union in the Area of Circulation of Medicines.” All manipulations with animals
were approved by the Bioethical Commission of the Zakusov Research Institute of
Pharmacology. The experiments were carried out from 10 to 16 pm. The test
substances were dissolved in saline or in distilled water and administered, i.p. The
animals of the control groups were injected with saline or with distilled water,
respectively.
2.2.4 Neuroprotective activity
A model of focal cerebral ischemia (ischemic stroke). Focal cerebral ischemia was
induced by transient middle cerebral artery occlusion (MCAO) using a modification
of the intraluminal filament model originally described in [20]. All surgical pro-
cedures were performed using titanium microsurgical instruments.
The rats were anesthetized with an i.p. injection of chloral hydrate (350 mg/kg)
as a 5% solution in saline. The right common carotid artery, internal carotid artery,
and external carotid artery were surgically exposed. A nylon suture (0.25 mm in
diameter) with a silicon-coated tip was inserted from the external carotid artery
into the internal carotid artery and then to the circle of Willis to occlude the origin
of the middle cerebral artery. After 1 h of MCAO, the suture was carefully removed
to induce reperfusion. Sham-operated rats (n = 6) underwent identical surgery
except that the suture was not inserted. During the surgery the body temperature
was maintained at 37.0  0.5°C using a heating pad. Three rats received MCAO
without any neurological deficits observed after awakening was excluded.
Design of the study. The rats with experimental ischemic stroke were randomly
divided into two groups: a “stroke” group with water treatment (n = 10) and
“stroke + GZK-111” group treated with GZK-111 (n = 7). Solution of GZK-111 in
distilled water was administered, i.p., at a dose 0.5 mg/kg 6 h after surgery and then
once a day for 6 days. Neurological functions were evaluated 3 and 6 days after
surgery using the limb-placing test [21]. The infarct volume was evaluated
according to [22] using 2,3,5-triphenyltetrazolium chloride (TTC) staining and
computerized image analysis 7 days after surgery.
Limb-placing test. Neurological functions were evaluated using the limb-placing
test [21], a modified version of the test described by De Ryck et al. [23]. This test
assessed the forelimb and hind limb responses to tactile and proprioceptive stimu-
lation and consisted of seven limb-placing tasks. The following scores were used to
detect impairment of the forelimb and hind limb: 2 points, the rat performed
normally; 1 point, the rat performed with a delay of more than 2 s and/or incom-
pletely; and 0 point, the rat did not perform the task. The maximum possible score
for the sham-operated rats for each side of the body was 14. Rats with experimental
stroke exhibited decreased neurological score on the side of the body which is
opposite to the ischemic lesion.
Evaluation of cerebral infarct volume. The cerebral infract volumes measured with
TTC staining were used to describe the severity of cerebral ischemia. The animals
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were deeply anesthetized with chloral hydrate (350 mg/kg, i.p.) and then decapi-
tated. The brains were removed rapidly, frozen in 20°C for 10 min and then
sectioned coronally into 2-mm-thick slices. The brain slices were incubated with 2%
TTC at 37°C for 30 min. Stained slices were fixed in 10% formalin solution. The
slices were digitalized on a flatbed scanner at 2400 dpi. The infarct volumes were
measured using the ImageJ (National Institutes of Health, Bethesda, MD, USA)
image analysis software program. The total infarct volume for each brain was
calculated by summation of unstained areas of the subsequent slices and
multiplying by the thickness (2 mm).
Nootropic antiamnesic activity. The antiamnesic effect of the substances was
evaluated by their ability to prevent impaired reproduction of the conditioned
passive avoidance reflex (passive avoidance reaction) caused by electroconvulsive
shock (ECS). Compounds GZK-111 and GZK-121 were administered once, i.p., at
the doses of 0.1, 0.5, and 1.0 mg/kg 40 min before training. Control animals were
injected with the same volume of physiological saline.
Passive avoidance reaction was developed in rats in a certified Lafayette Instru-
ment Co installation (USA) according to the method of [24] using a single training
procedure. The illuminated start platform (25  7 cm) was connected to a dark
40  40  40 cm chamber equipped with an electrified floor through a square
guillotine door. The animal was placed on the start platform with its tail to a dark
chamber. When governed by the hole exploratory behavior, the rat found the
entrance and passed into the dark compartment; the hole was closed. In the dark
chamber, eight unavoidable electric pain stimuli were applied through the floor to
the rat (the training current was 0.45 mA, the duration of each pulse was 1 s, and
the interval between consecutive pulses was 2 s). Immediately after this, the rat was
removed from the dark chamber and subjected to EKS (250 V, 120–122 mA, 0.1 s)
applied transcorneally using a certified Harvard apparatus (Germany). After 24 h,
the animal was again placed on the illuminated platform for learning test. The latent
period of the first animal entry into the dark chamber was recorded. Antiamnesic
activity (AA) was calculated as Eq. (1):
AA% ¼
LPtest LPamn
LPcontrol LPamn
 100% (1)
where AA% is antiamnesic activity, LPtest is the average latent period of entry
into the chamber in the animals administered with the test compound and subjected
to amnesia, LPamn is the average period of entry into the chamber in the animals
administered with 0.9% NaCl and subjected to amnesia, and LPcontrol is the
average latent period of entry into the chamber in animals administered with 0.9%
NaCl without amnesia.
Antihypoxic activity was studied in a model of normobaric hypoxia with
hypercapnia (“canned” hypoxia), according to [25]. Tests were performed on ani-
mals of the same weight (scatter in groups of ≤2 g). Each group consisted of 10
animals. The substances were administered, i.p., in saline 1 h before the start of the
experiment. Antihypoxic activity of the compounds was studied at doses of 0.1, 0.5,
and 1.0 mg/kg. Control animals received an equivalent volume of saline. Animals
were placed singly into 200 cm3 containers that were hermetically sealed. Deaths of
animals were recorded as the final agonal gasp.
Anxiolytic activity was studied in an elevated plus maze test according to
Pellow [26]. Compounds were administered once, i.p., 15 min before the experi-
ment. GZK-111 was administered at doses of 0.75, 1.5, and 3.0 mg/kg and GZK-121
at a dose of 1.5 mg/kg. The control animals were administered with the saline. The
apparatus consisted of four arms elevated 60 cm above the floor, with each arm
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positioned at 90° relative to the adjacent arms. Two opposite arms were enclosed
with high opaque walls (50  15  30 cm), and the other arms were open
(50  15  1 cm) connected via a central area (14  14 cm) to form a plus sign. At
the beginning of the experiment, the rats were placed in the center of the maze,
randomly orientated relative to the arm entrance. The behavior of the animals was
evaluated within 5 min. The following indicators were recorded: the number of
visits to all arms, the number of visits to open arms, the time spent in all arms, and
the time spent in open arms. The anxiolytic effect of the compound was estimated
by the increase in the number of visits to the light arms and in the time spent in the
light arms and on the central platform.
Antidepressant-like activity was assessed in a forced swimming test [27]. Mice
were placed into cylinders (30 cm high and 10 cm in diameter), filled in two-thirds
with water at a temperature of 22°C for 5 min; the time of preservation of the
characteristic immobilization posture (rejection of active defensive and research
behavior) was estimated. The behavior of animals was recorded using a video camera.
Video recording of the experiment was processed in semiautomatic mode using the
RealTimer program (Open Joint-Stock Company Open Science LLC). A decrease in the
immobilization duration was regarded as a manifestation of antidepressant activity.
Analgesic activity. The hot plate test was used to evaluate the nociceptive
response. Latent reaction period (the time before the hind paw pulling and/or
jumping) was recorded with a Ugo Basile analgesimeter (Italy). 1–2 hours before the
experiment, animals were selected following the basic response in the experimental
model conditions and excluding mice that remained on a plate heated to 55  0.5°C
for longer than 10 s. A latent period of 20 s (cutoff value) was regarded as 100%
analgesia. Hot plate tests were performed before and 30, 60, 90, and 120 min after i.
p. drug injection. If no response occurred within 20 s, the mice were removed from
the hot plate to avoid tissue injury. The percentage of the maximum possible effect
(% MPE) was calculated as follows: postdrug latency predrug latency
 

100= cutoff value predrug latency
 
.
Statistical analysis of the biological results was performed using the standard
software package “Statistica 10.0” (StatSoft, Inc., USA). To evaluate statistically
significant differences between the experimental and control groups of animals, the
following tests were used: nonparametric Mann-Whitney U test for nootropic,
anxiolytic, antihypoxic, and neuroprotective effects, the unpaired Student t-test for
antidepressant effect, and Duncan criterion for analgesic effect. The means and
standard errors of the mean (m  SEM) were calculated. Kruskal-Wallis ANOVA
followed by Dunn’s posttest was used to compare three or more samples in in vitro
experiments. The means and standard errors of the mean (m SD) were calculated.
The results were evaluated as significant at p ≤ 0.05.
3. Results and discussions
3.1 Synthesis of GZK-111
N-Phenylacetyl-glycyl-L-proline ethyl ester was prepared according to Figure 1
by the mixed anhydride method under Anderson conditions [28] using isobutyl
chloroformate. N-phenylacetylglycine obtained from glycine and phenylacetic acid
chloride according to Schotten-Baumann procedure [29] was used as carboxylic
component, and proline ethyl ester obtained with thionyl chloride in absolute etha-
nol according to Brenner method [30] was used as amine component. The D-
enantiomer of GZK-111 (GZK-121) was prepared by the same procedure.
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3.2 Biotransformation of GZK-111 to CPG
Synthesized GZK-111 was subjected to biotransformation in the presence of
plasma enzymes to show the fundamental possibility of its conversion to CPG. The
initial plasma contained endogenous CPG at a concentration of 1 μM, according to RP
HPLC. Upon GZK-111 incubation with plasma at 37°C for 10 h, an increase of the
CPG peak and appearance of a peak corresponding to the retention time of the
compound with an open carboxyl group, N-phenylacetyl-glycyl-L-proline, were
observed (see Figure 2). Thus, CPG is actually formed from GZK-111 in the presence
of blood plasma enzymes. The scheme of GZK-111 metabolism is shown in Figure 3.
3.3 Pharmacological effects of GZK-111
Based on the previously established pharmacological effects of CPG, the phar-
macological activity of GZK-111 (viz., neuroprotective, antiamnesic, antihypoxic,
anxiolytic, antidepressant-like, and analgesic effects) was studied.
The neuroprotective effect of GZK-111 was studied in vitro in a 6-OHDA
toxicity model in SH-SY5Y cells (cellular model of Parkinson’s disease) [19, 31],
which demonstrated the neuroprotective effect of CPG previously [6]. GZK-111
was introduced 24 h before 6-OHDA, because pharmacological effects of its metab-
olite (CPG) were probably caused by BDNF synthesis [12], which took no less than
6 h [32]. When introduced 24 h before the injury, GZK-111 was revealed to have
neuroprotective activity at concentrations of 107 and 106 M (Figure 4). The
range of active concentrations of CPG was 108–105 M in this model [6].
The neuroprotective activity of GZK-111 was studied in vivo in a model of
ischemic stroke caused by transient occlusion of the middle cerebral artery in rats,
according to [20]. This model allows to simulate the most common cerebrovascular
accident—an extensive ischemic stroke in the middle cerebral artery basin—and
provides a reproducible volume of ischemic injury [33]. The compound was admin-
istered, i.p., at a dose of 0.5 mg/kg/day for 7 days; the first injection was given 6 h
after surgery. The GZK-111 dose was taken accordingly to the results of other phar-
macological studies (see Tables 1 and 2). The duration of substance introduction
corresponds to the period of poststroke treatment in a hospital with consideration to
differences in the metabolic rates of animals and humans [34]. The first administra-
tion of the compound 6 h after ischemia is explained by preservation of penumbra
zone during this period [35], which makes it possible to decrease the volume of
ischemic damage. Neurological functions were evaluated 3 and 6 days after surgery
using the limb-placing test [21]. The infarct volume was evaluated 7 days after
surgery according to [22] with 2,3,5-triphenyltetrazolium chloride staining and com-
puterized image analysis. GZK-111 was found to have pronounced neuroprotective
effects, reducing the volume of the infarct zone by 1.6 times (Figure 5) and improv-
ing the neurological status of animals by approximately 30% (Figure 6).
The neuroprotective activity of CPG (1.0 mg/kg, i.p., subchronic) was revealed
previously in a model of incomplete global cerebral ischemia induced by permanent
bilateral common carotid arteries occlusion in rats [7].
Figure 1.
The scheme of synthesis of N-phenylacetyl-glycyl-L-proline ethyl ester enantiomers.
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The nootropic antiamnesic effect of GZK-111 was evaluated by its ability to
prevent impaired reproduction of the conditioned passive avoidance reflex (passive
avoidance reaction) in rats caused by electroconvulsive shock (ECS) by the Ader
method [24]. The test is based on the inborn hole exploratory behavior of rodents.
Figure 2.
The investigation of GZK metabolism in blood plasma by HPLC method. (A) Standards: (1) cyclo-L-
prolylglycine, (2) N-phenylacetyl-glycyl-L-proline, and (3) N-phenylacetyl-glycyl-L-proline ethyl ester;
(B) control blood plasma; (C) blood plasma + GZK-111, 10-h incubation.
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An animal learns not to enter the dark compartment using electric pain stimulation.
Once the animal is subjected to EKS after training, the memorial trail is erased, and
the animal again enters the dark chamber. Nootropic activity is defined as the
ability to decrease the amnesic effect of ECS. GZK-111 was demonstrated to have
antiamnesic activity at doses of 0.1, 0.5, and 1.0 mg/kg, i.p. (see Table 1), i.e., at
least in the same dose range as CPG. Unlike the L-isomer, the D-stereoisomer of
GZK-111, ethyl ester of N-phenylacetyl-glycyl-D-proline (GZK-121), had no
antiamnesic activity.
Thus, GZK-111 possesses an antiamnesic activity similarly to CPG, and its effect
is stereospecific, like that of CPG. However, if the D-enantiomer of CPG exhibits a
pro-amnesic effect, the D-enantiomer of GZK-111 (GZK-121) has no activity. The
possible explanation is that D-CPG blocks the receptor, while GZK-121 is not
metabolized to CPG at all.
The antihypoxic activity of GZK-111 was studied in the normobaric hypoxia
test with hypercapnia (“canned” hypoxia) in mice, which is the simplest method to
assess antihypoxic activity [25]. GZK-111 was administered at doses of 0.1, 0.5, and
1.0 mg/kg, i.p., 60 min before test. Likewise CPG, the compound was found to
Figure 3.
The scheme of GZK-111 metabolism.
Figure 4.
The neuroprotective effect of GZK-111 in a 6-OHDA toxicity model, SH-SY5Y cells. Notes: *p < 0.05
comparison with the control, ^p < 0.05 comparison with the damage group (Kruskal-Wallis ANOVA test with
Dunn’s post hoc).
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exhibit an antihypoxic effect at a dose of 0.5 mg/kg, significantly increasing the life
expectancy of animals (see Table 2). The stereoisomer GZK-121 at doses of 0.1, 0.5,
and 1.0 mg/kg showed no antihypoxic activity in this test.
The anxiolytic activity of GZK-111 was studied in rats at doses of 0.75, 1.5, and
3.0 mg/kg, i.p., using the elevated plus maze test (EPM) according to Pellow [26].
This test is the primary model for anxiolytic activity detection; it is based on the
conflict between rodents’ inherent fear of open spaces and natural exploratory
behavior. A significant anxiolytic effect was observed at a dose of 1.5 mg/kg. GZK-
111 increased the time rats spent in the open arms by 12 times relative to the control,
which is comparable with the effect of CPG. The enantiomer, GZK-121, was
inactive at a dose of 1.5 mg/kg (see Table 3).
Compound Dose, mg/kg, i.p. (n = 10)
Control 0.1 0.5 1.0
Life expectancy, min
L-CPG [6] 20.9  0.6 20.2  0.8 24.0  0.7* 25.0  1.6**
D-CPG [40] 21.8  1.7 23.3  1.5 22.7  0.5 22.3  1.4
GZK-111 27.1  0.9 25.2  0.5 30.2  0.7* 26.2  0.3
GZK-121 25.8  0.8 23.9  0.7 26.0  0.7 23.5  0.8
Notes: The outbred white male mice were used in the experiments;
n, number of animals;
*p < 0.05;
**p < 0.01 comparison with the control (Mann-Whitney U test).
Table 2.
The effects of GZK-111 and GZK-121 in normobaric hypoxia test with hypercapnia in mice, compared to
CPG.
Compound Dose, mg/kg, i.p. (n = 10) Latent period, s Effect, %
Control Amnesia Amnesia + compound
L-CPG [3] 0.05 91  34 19  8° 25  7 +8
0.1 91  34 19  8° 73  26* +75*
1.0 91  34 19  8° 43  19* +33*
D-CPG [39] 0.1 113  12 48  11° 27  8* 32*
GZK-111 0.1 180  0 129  28° 169  10* +76*
0.5 180  0 100  25 176  6* +95*
1.0 180  0 129  28° 179  2* +98*
GZK-121 0.5 180  0 95  31° 133  23 +44
Notes: n, number of animals;
°р < 0.05 comparison with the control;
*р < 0.05 comparison with the amnesia group (Mann-Whitney U test with a Bonferroni correction).
Antiamnesic activity (AA) was calculated as follows: AA% ¼ LPtestLPamnLPcontrolLPamn 100%: where AA% is antiamnesic
activity, LPtest is the average latent period of entry into the chamber in the animals administered with the test
compound and subjected to amnesia, LPamn is the average period of entry into the chamber in the animals
administered with 0.9% NaCl and subjected to amnesia, and LPcontrol is the average latent period of entry into the
chamber in animals administered with 0.9% NaCl without amnesia.
Table 1.
The effects of GZK-111 and GZK-121 in passive avoidance reaction test, compared to CPG.
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The antidepressant-like effect of GZK-111 was studied in the forced swimming
test [27], one of the most widely used for this purpose [36]. The test is based on the
ability of antidepressants to reduce the time of immobility in case of unavoidable
swimming of the animal in a cylinder with water. The study was performed in mice
at daily i.p. administration at a dose range of 0.01–20.0 mg/kg within 7 or 14 days.
Figure 5.
GZK-111 reduces the cerebral infarct volumes in rats with experimental stroke. Notes: Morphometric
measurements of infarct volume were performed using TTC staining. The data are presented as mean  SEM.
*p = 0.05 compared to the “stroke” group (Mann-Whitney U test).
Figure 6.
GZK-111 improves neurological status in rats with experimental stroke. Notes: Neurological status is given for
the injured side of the body (which is the opposite to the ischemic lesion) in the limb-placing test. The data are
presented as mean  SEM. *p = 0.003 compared to the “sham” group, #p = 0.01 compared to the “stroke”
group (Mann-Whitney U test).
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The tricyclic antidepressant amitriptyline (10.0 mg/kg, i.p.) was used as a compar-
ison drug. GZK-111 administered at a dose of 10 mg/kg for 7 days was established to
statistically significantly reduce the immobility time by 11% (Table 4), which is
comparable to the effect of amitriptyline at a dose of 10 mg/kg.
With a 14-day administration, GZK-111 had a significant antidepressant effect at
a dose of 10 mg/kg, i.p., and showed a tendency to decrease immobility time at a
dose of 1.0 mg/kg, i.p. (p = 0.08) and 10 mg/kg p.o. (p = 0.06) (Table 5).
Recently, the antidepressant activity of started CPG was also discovered in the
forced swimming test in mice (Table 5) [9] and in an experimental model of
learned helplessness in rats [10] at i.p. administration for 14 days.
The analgesic properties of GZK-111 were determined in the hot plate test in
inbred male C57Bl/6 mice [37] at acute i.p. administration at doses of 0.5, 1.0, 2.0,
and 4.0 mg/kg. This test was widely used to study the pain sensitivity in rodents at
supraspinal level, and the effectiveness of analgesics evaluates the pain response on
paw pad contact with a hot surface; the time until the hind paw pulling and/or
jumping is measured. The average baseline nociceptive response for C67Bl/6 mice
was 8.2  0.2 s. GZK-111 showed no analgesic effect (F(4, 44) = 11,163,
p = 0,36,098) 30 min after administration at each of the doses studied. At a dose of
2.0 mg/kg, GZK-111 statistically significantly increased the latent period of the
nociceptive reaction (F(4, 44) = 3.1489, p = 0.02319) 60 min (p < 0.01) and
120 min (p < 0.05) after administration, compared with the control group. At a
Compound Dose, mg/kg, i.p. (n = 10) Number of entries into the
open arms
Time spent in the open
arms
m % s %
L-CPG [4] Control 1 0.20 100 2.15 100
0.1 1.79* 895* 13.8* 641*
1.0 0.25 125 1.46 68
Control 2 0.58 100 6.38 100
0.05 1.60** 276** 57.4** 900**
0.2 1.50 259 19.3 303
D-CPG [4] Control 0.20 100 2.15 100
0.05 0.34 170 3.87 180
0.1 0.26 132 2.58 120
GZK-111 Control 0.9  0.6 100 4.8  2.5 100
0.75 1.3  0.5 170 14.8  7.0 180
1.50 3.2  1.1 355 58.2  13.3** 1212**
3.0 1.0  0.5 132 6.4  2.9 120
GZK-121 Control 0.2  0.2 100 4.1  1.5 100
1.5 0.2  0.2 100 4.7  1.5 114
Notes: Number of entries into the open arms and time spent in the open arms were taken as 100% for control animals.
n, number of animals; m, number of entries into the open arms of the maze;
*p < 0.05;
**p < 0.001 comparison with the control (Mann-Whitney U test).
Table 3.
The effects of GZK-111 and GZK-121 in EPM test in rats, compared to CPG.
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dose of 4 mg/kg, an increase of the reaction thresholds induced by GZK-111 was
observed after 90 min (F(4, 44) = 3.8743, p = 0.00881) that persisted for up to 2 h
(F(4, 44) = 3.2141, p = 0.02124), compared with the control group (p < 0.05 and
p < 0.05, respectively) (Figure 7). The data obtained indicate that GZK-111
exhibits dose-dependent analgesic activity, like CPG in rats [38].
Experimental
groups
Dose, mg/kg, i.p.
(n = 10)
Immobilization
time, s
Immobilization time compared
to the control, %
Experiment 1
Control 0.0 235.8  11.8 100
GZK-111 0.1 240.2  19.8 101
GZK-111 0.5 235.3  17.7 100
GZK-111 1.0 240.0  22.1 101
GZK-111 5.0 253.9  9.2 108
Amitriptyline 10.0 218.5  17.9* 93
Experiment 2
Control 275.3  8.7 100
GZK-111 0.01 260.1  7.3 94
GZK-111 5.0 268.7  10.2 98
GZK-111 10.0 245.5  9.1* 89
GZK-111 20.0 259.9  9.2 94
Notes: Immobilization time was taken as 100% for control animals.
n, number of animals;
*р < 0.05, the statistical significance of the differences relative to control group by the unpaired t-Student criterion.
Table 4.
The effect of GZK-111 on immobilization time in the Porsolt forced swimming test in mice after 7-day
administration.
Compound Dose, mg/kg, i.p.
(n = 10)
Immobilization time,
s
Immobilization time compared
to the control, %
GZK-111 Control 180.1  10.7 100
0.1 188.4  9.3 105
1.0 163.2  11.2 (p = 0.08) 91
10.0 157.7  9.2* 88
10.0 (p.o.) 160.3  10.4
(p = 0.06)
89
CPG [9] Control 139  8 100
1.0 97  6# 70
2.0 101  8# 73
Fluoxetine [9] 10.0 87  9# 63
Notes: Immobilization time was taken as 100% for control animals.
n, number of animals;
*р < 0.05, the statistical significance of the differences relative to control group by the unpaired t-Student criterion;
#p < 0.05;
Table 5.
The effect of GZK-111 on immobilization time in the Porsolt forced swimming test in mice after 14-day
administration, compared to CPG.
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4. Conclusions
Thus, GZK-111 exhibits nootropic, anxiolytic, antihypoxic, antidepressant,
neuroprotective, and analgesic effects being characteristic to CPG. The compound
is similar to CPG both in the spectrum of activities and in the stereospecificity and
its nature. The ampakine CPG identical to endogenous one was proven to form
during the fermentolysis of GZK-111. Therefore, GZK-111 can be considered as a
“prodrug” of CPG and a pharmacologically active pro-ampakine with a BDNF-ergic
mechanism of action.
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Figure 7.
GZK-111 influences the pain response threshold during thermal stimulation in C57BL/6 mice. X-axis, time
of the effect development after substance administration (min); y-axis, maximum possible effect (MPE), %.
*p < 0.05; ** p < 0.01, statistically significant in relation to the corresponding control; according to Duncan
criterion, the number of animals in groups n = 10; data are presented as mean values.
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